Measuring fatigue in patients with multiple sclerosis with standardized methods in German speaking areas;Messbarkeit von fatigue bei multipler sklerose mithilfe standardisierter methoden im deutschsprachigen raum

Fortschritte der Neurologie Psychiatrie

Volumn 74, Issue 9, 2006, Pages 497-502

  Reske, D ^a   Pukrop, R ^a   Scheinig, K ^a   Haupt, W F ^a   Petereit, H F ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FATIGUE; FEMALE; GERMANY; HUMAN; MALE; MULTIPLE SCLEROSIS; RATING SCALE; RECURRENT DISEASE; RELIABILITY; VALIDITY;

ADULT; FACTOR ANALYSIS, STATISTICAL; FEMALE; GERMANY; HUMANS; LANGUAGE; MALE; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MUSCLE FATIGUE; REPRODUCIBILITY OF RESULTS;

EID: 33749123436     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-932189     Document Type: Article

References (17)

1. Branas O, Jordan R, Fry-Smith A, Burls A, Hyde C. Treatments for fatigue in multiple sclerosis: a rapid and systemic review. Health Technol Assess 2000; 4: 1-61
2. Flachenecker P, Bihler I, Gottschalk M, Toyka KV, Rieckmann P. Cytokine mRNA expression in patients with multiple sclerosis and fatigue. Multiple Sclerosis 2004; 10: 165-169
3. Krupp LB, Rizvi SA. Symptomatic therapy for underrecognized manifestations of multiple sclerosis. Neurology 2002; 58 (suppl 4): S323-339
4. Sheean GL, Murray NM, Rotwell JC, Miller DH, Thompson AJ. An electrophysiological study of mechanism of fatigue in multiple sclerosis. Brain 1997; 120: 299-315
5. Rudick RA, Barna BP. Serum interleukin 2 and soluble interleukin 2 receptor in patients with multiple sclerosis who are experiencing severe fatigue. Arch Neurol 1990; 47: 254-255
6. Chaudhuri A, Behan PO. Fatigue and basal ganglia. J Neurol Sci 2000; 179 (suppl. 1, pt 2): 34-42
7. Krueger JM, Obal Jr F, Fang J. Humoral regulation of physiological sleep: cytokines and GHRH. J Sleep Res 1999; 8 Suppl 1: 53-59
8. 18F-fluorodeoxyglucose positron emission tomography study. Neurology 1997; 48: 1566-1571
9. Krupp LB. Assessment and treatment of fatigue in multiple sclerosis. In: Kappos L, Johnoson K, Kesselring J, Radü EW (Hrsg). Multiple Sclerosis - tissue distruction and repair. Martin Dunitz Ltd, 2001: 179-180
10. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46: 1121-1123
11. Fisk JD, Ritvo PG, Ross L, Haase DA, Marrie TJ, Schlech WF. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Inf Dis 1994; 18: S79-83
12. Schwartz JE, Jandorf L, Krupp LB. The measurement of fatigue: a new instrument. J Psychosom Res 1993; 37: 753-762
13. Krupp LB, Coyle PK, Doscher C, Miller A, Cross AH, Jandorf L, Halper J, Johnson B, Morgante L, Grimson R. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology 1995; 45: 1956-1961
14. Multiple Sclerosis Council for Clinical Practice Guidelines. Fatigue and multiple sclerosis: evidence-based management strategies for fatigue in multiple sclerosis. Multiple Sclerosis Council for Clinical Practice Guidelines, 1998
15. Krupp LB, Coyle PK, Cross AH. Amelioration of fatigue with pemoline in patients with multiple sclerosis. Ann Neurol 1989; 26: 155-156
16. Flachenecker P, Kümpfel T, Kallmann B et al. Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters. Multiple Sclerosis 2002; 8: 523-526
17. Flachenecker P, Muller G, Konig H, Meissner H, Toyka KV, Rieckmann P. Fatigue and multiple sclerosis. Development and validation of a new German assessment scale (WEIMuS). Nervenarzt, 2005 (in print)